185 related articles for article (PubMed ID: 37738533)
21. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xue X; Qian J
Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars in psoriasis: the future or not?
Kellen R; Goldenberg G
Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
24. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
[TBL] [Abstract][Full Text] [Related]
26. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
Xue X; Truong B; Qian J
Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
[TBL] [Abstract][Full Text] [Related]
27. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
28. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
29. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
31. Sample Size for Biosimilar Trials: In Defense of Synthesis.
Clark T; Jo SJ; Phillips A
Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
[TBL] [Abstract][Full Text] [Related]
32. [Revised version of the statement by the DGRh on biosimilars-update 2017].
Braun J; Lorenz HM; Müller-Ladner U; Schneider M; Schulze-Koops H; Specker C; Strangfeld A; Wagner U; Dörner T
Z Rheumatol; 2018 Feb; 77(1):81-90. PubMed ID: 29383440
[TBL] [Abstract][Full Text] [Related]
33. Biosimilars-Emerging Role in Nephrology.
Wish JB
Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
[TBL] [Abstract][Full Text] [Related]
34. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.
; Baldziki M; Brown J; Chan H; Cheetham TC; Conn T; Daniel GW; Hendrickson M; Hilbrich L; Johnson A; Miller SB; Moore T; Motheral B; Priddy SA; Raebel MA; Randhawa G; Surratt P; Walraven C; White TJ; Bruns K; Carden MJ; Dragovich C; Eichelberger B; Rosato E; Sega T
J Manag Care Spec Pharm; 2015 Jan; 21(1):23-34. PubMed ID: 25562770
[TBL] [Abstract][Full Text] [Related]
35. Similar names for similar biologics.
Casadevall N; Felix T; Strober BE; Warnock DG
BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
[TBL] [Abstract][Full Text] [Related]
36. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
Tu CL; Wang YL; Hu TM; Hsu LF
BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
[TBL] [Abstract][Full Text] [Related]
39. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review.
Allegretti JR; Brady JH; Wicker A; Latymer M; Wells A
Adv Ther; 2024 May; 41(5):1775-1794. PubMed ID: 38466559
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
